Private Equity 8 Hours

Last updated: May 22, 2026, 5:30 PM ET

Deal Flow & Valuations Highlighting inflated ARR revealed that several AI startups are reporting revenue metrics that double actual cash receipts, a practice investors accept to justify multi‑hundred‑million‑dollar valuations. The same funding surge appears in the weekly roundup, where record‑size rounds saw a $1.2bn infusion for a medical‑device AI platform and a $850mn deal for a defense‑tech aerospace venture, underscoring venture capital’s appetite for high‑growth, metric‑heavy sectors.

Secondary Market Activity Frontenac’s asset sale moved forward as Churchill Asset Management and 50 South Capital co‑led the purchase of the industrial‑focused CV portfolio, positioning the buyers to capture upside from post‑pandemic supply‑chain rebalancing. The transaction, valued at roughly €750mn, signals growing confidence among secondary investors in repurposing legacy industrial assets for ESG‑aligned upgrades.

Sector Targeting PE interest in pain care showed Charterhouse, Iron Path and Revelar Capital lining up bids for niche pain‑management operators, while Charlesbank’s merger with a Nordic medtech firm created a consolidated orthopedics platform valued at €1.1bn. These moves reflect private equity’s strategy to consolidate fragmented healthcare niches where recurring revenue and regulatory barriers promise stable cash flows.